SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
April 2, 2019
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
(Commission File Number)
(IRS Employer Identification No.)
2505 Meridian Parkway, Suite 100
(Address of principal executive offices)
Registrant’s telephone number, including area code: (919) 806-1074
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Termination of a Material Definitive Agreement.
On April 2, 2019, Chimerix, Inc. (the “Company”) received notification from ContraVir Pharmaceuticals, Inc. (“ContraVir”) of its intention to terminate the License Agreement by and between the Company and ContraVir, dated December 17, 2014 (the “License Agreement”). The termination of the License Agreement will be effective on June 1, 2019.
Pursuant to the License Agreement, the Company granted ContraVir rights for the development and commercialization of CMX157, the Company’s novel lipid acyclic nucleoside phosphonate, for certain antiviral indications. Upon the effectiveness of the termination of the License Agreement, the Company will reacquire all worldwide rights to CMX157.
ContraVir made the decision to terminate the License Agreement following its decision to no longer pursue development of CMX157.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 4, 2019
/s/ Timothy W. Trost
Timothy W. Trost
Principal Financial and Accounting Officer